The purpose of this study is to determine the safety and tolerability of Anti-MIF Antibody in subjects with lupus nephritis.

Inclusion Criteria:

• Signed and dated written informed consent obtained from the subject
• Males and females of age 18 years and older at the time of screening
• Established diagnosis of systemic lupus erythematosus (SLE) according to the American College of Rheumatology classification criteria
• Documented renal biopsy evidence of proliferative glomerulonephritis prior to screening
• Urine protein-to-creatinine ratio > 0.5 (mg/mg)

Exclusion Criteria:

• Any significant health problem other than lupus or lupus nephritis